Gardner Syndrome Treatment Market Report 2026

The gardner syndrome treatment market size has grown strongly in recent years. It will grow from $20.13 billion in 2025 to $21.25 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to identification of fap-related syndromes, advancement in endoscopic monitoring, availability of surgical interventions, improved cancer surveillance, genetic testing adoption.

The gardner syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $26.09 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth in precision oncology approaches, expansion of prophylactic treatment strategies, increased awareness of inherited cancer syndromes, development of targeted therapies, integration of genetic counseling services. Major trends in the forecast period include increased focus on early genetic screening, rising use of preventive surgical interventions, expansion of long-term surveillance programs, growing role of multidisciplinary cancer care, emphasis on family-based genetic counseling.

The rising level of medical tourism is expected to support the growth of the Gardner syndrome treatment market in the coming years. Medical tourism involves patients traveling across countries or regions to access medical care, healthcare services, or surgical procedures. Popular medical tourism destinations offer advanced medical technologies and treatment options for patients seeking the latest therapeutic approaches for Gardner syndrome. For example, in May 2024, the Ministry of Health and Welfare (MOHW), a South Korea-based national health and social welfare authority, reported that South Korea received 606,000 foreign patients in 2023, representing a 2.4-fold increase compared with previous years. Therefore, the growth in medical tourism is contributing to the expansion of the Gardner syndrome treatment market.

The increasing demand for personalized medicine is also expected to propel the growth of the Gardner syndrome treatment market. Personalized medicine is a healthcare approach that customizes treatments based on an individual’s genetic makeup, environmental factors, and lifestyle to improve clinical outcomes. Demand for personalized medicine is rising as patients and healthcare providers increasingly prefer therapies tailored to genetic profiles, which can enhance treatment effectiveness and minimize adverse effects. Gardner syndrome management supports this trend, as it often requires targeted, genetics-based interventions aligned with specific mutation profiles, thereby encouraging the adoption of personalized therapeutic strategies. For instance, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Of these, seven were oncology drugs, while three addressed other diseases and conditions. Consequently, the growing emphasis on personalized medicine is driving the Gardner syndrome treatment market.

Companies operating in the Gardner syndrome treatment market are increasingly introducing new products to maintain and strengthen their market presence. For example, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, launched Fruzaqla (fruquintinib) following approval from the US Food and Drug Administration (FDA). Fruzaqla (fruquintinib) is a targeted therapy indicated for the treatment of metastatic colorectal cancer (mCRC) in adults and is the first drug designed to inhibit all three subtypes of vascular endothelial growth factor (VEGF) receptor kinases. Patients with Gardner syndrome face an elevated risk of developing colorectal cancer, for which Fruzaqla (fruquintinib) is used as a treatment option.

Major companies operating in the gardner syndrome treatment market are Pfizer Inc., Sanofi S.A., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., AstraZeneca plc, Bristol Myers Squibb Company, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Daiichi Sankyo Company Ltd., Mirati Therapeutics Inc., Plus Therapeutics Inc., Processa Pharmaceuticals Inc., Shanghai Henlius Biotech Inc.

North America was the largest region in the gardner syndrome treatment market in 2025. The regions covered in the gardner syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gardner syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the gardner syndrome treatment market by raising prices for imported endoscopy equipment, pharmaceutical therapies, imaging systems, and surgical supplies. Hospitals and specialty clinics in Asia-Pacific and Latin America are most impacted due to global sourcing of gastrointestinal and oncology devices. These higher costs can limit early detection and treatment access. However, tariffs are encouraging local medical device manufacturing and pharmaceutical production, strengthening long-term care infrastructure.

The gardner syndrome treatment market research report is one of a series of new reports that provides gardner syndrome treatment market statistics, including gardner syndrome treatment industry global market size, regional shares, competitors with a gardner syndrome treatment market share, detailed gardner syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the gardner syndrome treatment industry. This gardner syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gardner syndrome is a form of familial adenomatous polyposis (FAP) that leads to the development of multiple colon polyps and various cancerous or noncancerous tumors. Treatment for Gardner syndrome involves close monitoring of polyps through lower gastrointestinal tract endoscopy, which helps control and limit the growth of colon polyps.

The main cancer-related conditions involved in Gardner syndrome treatment include dilated cardiomyopathy, skeletal myopathy, neutropenia, and others. Dilated cardiomyopathy is a heart muscle disorder in which the heart chambers, particularly the ventricles, become thin, stretched, and enlarged. The therapeutic options include nonsteroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, which are used across hospitals, specialty clinics, and other healthcare settings.

The gardner syndrome treatment market includes revenues earned by entities by providing services such as screenings of colonoscopy, sigmoidoscopy, and EGD (esophagogastroduodenoscopy) services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.